Ezra Innovations

EZRA Innovations LLC is a generic drug company focused on manufacturing the most difficult to reproduce generic drugs.

EZRA has a unique opportunity to develop generic drugs which are versions of popular branded drugs with little generic competition due to the brand's initial technological design.

Most of these opportunities are categorized as once-daily drugs. These are not inexpensive $4 dollar generic drugs, but rather drugs that are $80 dollars in price or greater for a 30 day supply.

Learn More...

Currently Employeed at Ezra Innovations

Michael Geranen – Chairman / CEO

Terrence L. Shockley – President (Consulting)

Brett Mathews, CPA – Consulting CFO

Dr. Shirish Shah, Ph.D. – Consultant, Regulatory Affairs

Robert H. Lake, Executive Vice President, (Consulting) Sales & Marketing / Director

Dr. Tery Baskin, Pharm D - Advisory Board Member

Dr. James K. Hendren, Ph.D. - Board Member - Managing Advisor

Dr. Michael Douglas, Ph.D. - Advisory Board Member

Operational Update:

EZRA opened an initial round of financing of $6.5m in December, 2010. As of May, 2012 EZRA has raised $5.4M USD with follow on commitments to fund projects as needed.

EZRA's first generic drug target has currently moved into manufacturing. EZRA's second drug target will be moved into manufacturing q3 2012. Given the promising support of multiple partners in the drug industry, including support of financial partners, and the EZRA Team, the opportunity for EZRA's success is extremely promising.